Background: Extracellular ATP binds to purinergic receptors and promotes inflammatory responses. We tested whether oxidized ATP (oATP), P2X7 receptor antagonist can attenuate acute kidney allograft rejection. Methods: Brown Norway kidney allografts were transplanted into Lewis recipients. Three groups were defined: oATP (n=8), cyclosporine A (n=6), and no treatment (n=8). On day 7, we assessed kidney allograft survival, function, and rejection characteristics. We further determined T-cell, B-cell, and macrophage response to oATP in vivo and in vitro and examined intragraft inflammatory gene transcripts. Results: Kaplan-Meier survival analyses demonstrated significantly better graft survival rates in oATP and CsA groups compared with no treatment (P<0.05). Similarly, serum creatinine (Scr) and BUN levels were significantly lower in oATP and CsA groups (P<0.05). oATP reduced both T cell-mediated rejection and antibody-mediated rejection, inhibited B-cell and T-cell activation, and downregulated intragraft IL-6 mRNA levels (P<0.0001). In vitro, oATP prevented proliferation in mixed lymphocyte reaction assays, and inhibited macrophage P2X7R activity in a dose-dependent manner. Conclusions: Our findings suggest that oATP mitigates kidney allograft rejection by inhibiting T-cell, B-cell, and macrophage activity and indicate a potential role for the purinergic system and oATP in solid organ transplantation.
Background: Extracellular ATP binds to purinergic receptors and promotes inflammatory responses. We tested whether oxidized ATP (oATP), P2X7 receptor antagonist can attenuate acute kidney allograft rejection. Methods: Brown Norway kidney allografts were transplanted into Lewis recipients. Three groups were defined: oATP (n=8), cyclosporine A (n=6), and no treatment (n=8). On day 7, we assessed kidney allograft survival, function, and rejection characteristics. We further determined T-cell, B-cell, and macrophage response to oATP in vivo and in vitro and examined intragraft inflammatory gene transcripts. Results: Kaplan-Meier survival analyses demonstrated significantly better graft survival rates in oATP and CsA groups compared with no treatment (P<0.05). Similarly, serum creatinine (Scr) and BUN levels were significantly lower in oATP and CsA groups (P<0.05). oATP reduced both T cell-mediated rejection and antibody-mediated rejection, inhibited B-cell and T-cell activation, and downregulated intragraft IL-6 mRNA levels (P<0.0001). In vitro, oATP prevented proliferation in mixed lymphocyte reaction assays, and inhibited macrophage P2X7R activity in a dose-dependent manner. Conclusions: Our findings suggest that oATP mitigates kidney allograft rejection by inhibiting T-cell, B-cell, and macrophage activity and indicate a potential role for the purinergic system and oATP in solid organ transplantation.
Authors: Philipp A Lang; Doron Merkler; Pauline Funkner; Namir Shaabani; Andreas Meryk; Caroline Krings; Carmen Barthuber; Mike Recher; Wolfgang Brück; Dieter Häussinger; Pamela S Ohashi; Karl S Lang Journal: Eur J Immunol Date: 2010-09 Impact factor: 5.532
Authors: J A Sullivan; E Jankowska-Gan; L Shi; D Roenneburg; S Hegde; D S Greenspan; D S Wilkes; L C Denlinger; W J Burlingham Journal: Am J Transplant Date: 2014-05-27 Impact factor: 8.086
Authors: N L Korpi-Steiner; D Sheerar; E B Puffer; C Urben; J Boyd; A Guadarrama; K Schell; L C Denlinger Journal: Cytometry B Clin Cytom Date: 2008-09 Impact factor: 3.058
Authors: Aparna Vidyasagar; Shannon R Reese; Omeed Hafez; Ling-Jin Huang; William F Swain; Lynn M Jacobson; Jose R Torrealba; Pierre-Emmanuel Chammas; Nancy A Wilson; Arjang Djamali Journal: Kidney Int Date: 2012-09-12 Impact factor: 10.612
Authors: A Loupy; M Haas; K Solez; L Racusen; D Glotz; D Seron; B J Nankivell; R B Colvin; M Afrouzian; E Akalin; N Alachkar; S Bagnasco; J U Becker; L Cornell; C Drachenberg; D Dragun; H de Kort; I W Gibson; E S Kraus; C Lefaucheur; C Legendre; H Liapis; T Muthukumar; V Nickeleit; B Orandi; W Park; M Rabant; P Randhawa; E F Reed; C Roufosse; S V Seshan; B Sis; H K Singh; C Schinstock; A Tambur; A Zeevi; M Mengel Journal: Am J Transplant Date: 2017-01 Impact factor: 8.086
Authors: Max Löhning; Andreas Hutloff; Tilmann Kallinich; Hans Werner Mages; Kerstin Bonhagen; Andreas Radbruch; Eckard Hamelmann; Richard A Kroczek Journal: J Exp Med Date: 2003-01-20 Impact factor: 14.307